SN38 polymeric nanoparticles: In vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan

International Journal of Pharmaceutics

Volumn 471, Issue 1-2, 2014, Pages 485-497

  Sepehri, Nima ^a,b   Rouhani, Hasti ^a,b   Tavassolian, Faranak ^a   Montazeri, Hamed ^c   Khoshayand, Mohammad Reza ^d   Ghahremani, Mohammad Hossein ^a   Ostad, Seyed Nasser ^a   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti tumor efficacy; Cytotoxicity; Irinotecan; PLGA nanoparticles; SN38

Indexed keywords

FIRTECAN; IRINOTECAN; NANOCARRIER; POLYGLACTIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG CARRIER; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TUMOR VOLUME; TUMOR XENOGRAFT; X RAY DIFFRACTION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; SOLUBILITY; SURFACE PROPERTY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG LIBERATION; FEMALE; HUMANS; LACTIC ACID; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; SURFACE PROPERTIES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902449520     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.05.046     Document Type: Article

References (37)

1. F. Ahmed, V. Vyas, A. Cornfield, S. Goodin, T. Ravikumar, and E. Rubin et al. In vitro activation of irinotecan to SN-38 by human liver and intestine Anticancer Res. 19 1998 2067 2071
2. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515
3. F. Atyabi, A. Farkhondehfai, F. Esmaeili, and R. Dinarvand Preparation of pegylated nano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice Acta Pharm. 59 2009 133 144
4. J.D. Byrne, T. Betancourt, and L. Brannon-Peppas Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Deliv. Rev. 60 2008 1615 1626
5. J. Cheng, B.A. Teply, I. Sherifi, J. Sung, G. Luther, and F.X. Gu et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery Biomaterials 28 2007 869 876 (Pubitemid 44667020)
6. F. Danhier, N. Lecouturier, B. Vroman, C. Jérôme, J. Marchand-Brynaert, and O. Feron et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation J. Control. Release 133 2009 11 17
7. M.E. Davis Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
8. S.N. Deming Multiple-criteria optimization J. Chromatogr. A 550 1991 15 25
9. N. de Moraes, J. Ambrosio, C.-A. de Magalhaes, E. Christine, W. Quintilio, and M.H.A. Santana et al. Poly-lactide-co-glycolide microparticle sizes: a rational factorial design and surface response analysis J. Nanosci. Nanotechnol. 6 2006 2403 2407 (Pubitemid 44599065)
10. R. Dinarvand, N. Sepehri, S. Manoochehri, H. Rouhani, and F. Atyabi Poly lactide-co-glycolide nanoparticles for controlled delivery of anticancer agents Int. J. Nanomedicine 6 2011 877
11. P. Ebrahimnejad, R. Dinarvand, A. Sajadi, M.R. Jaafari, A.R. Nomani, and E. Azizi et al. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines Nanomedicine 6 2010 478 485
12. P. Ebrahimnejad, R. Dinarvand, M.R. Jafari, S.A.S. Tabasi, and F. Atyabi Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38 Int. J. Pharm. 406 2011 122 127
13. Y. El-Malah, and S. Nazzal Hydrophilic matrices: application of Placket-Burman screening design to model the effect of POLYOX-carbopol blends on drug release Int. J. Pharm. 309 2006 163 170 (Pubitemid 43129479)
14. F. Esmaeili, R. Dinarvand, M.H. Ghahremani, S.N. Ostad, H. Esmaily, and F. Atyabi Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly (lactide-co-glycolide) nanoparticles Anticancer Drugs 21 2010 43 52
15. G. Hanrahan, and K. Lu Application of factorial and response surface methodology in modern experimental design and optimization Crit. Rev. Anal. Chem. 36 2006 141 151 (Pubitemid 44889522)
16. S. Jain, A. Mittal, K.A. Jain, R.R. Mahajan, and D.A. Singh Cyclosporin loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies Curr. Nanosci. 6 2010 422 431
17. C. Jin, L. Bai, H. Wu, W. Song, G. Guo, and K. Dou Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells Pharm. Res. 26 2009 1776 1784
18. D. Joshi, Y. Lan-Chun-Fung, and J. Pritchard Determination of poly (vinyl alcohol) via its complex with boric acid and iodine Anal. Chim. Acta 104 1979 153 160
19. Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51 1991 4187 4191
20. H. Maeda, G. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
21. O. Mert, G. EsendaǧlI, A.L. Doǧan, and A.S. Demir Injectable biodegradable polymeric system for preserving the active form and delayed-release of camptothecin anticancer drugs RSC Adv. 2 2012 176 185
22. N. Mondal, K.K. Halder, M.M. Kamila, M.C. Debnath, T.K. Pal, and S.K. Ghosal et al. Preparation, characterization, and biodistribution of letrozole loaded PLGA nanoparticles in Ehrlich Ascites tumor bearing mice Int. J. Pharm. 397 2010 194 200
23. L. Mu, and S. Feng A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS J. Control. Release 86 2003 33 48 (Pubitemid 35469120)
24. L. Mu, and S.-S. Feng PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio Pharm. Res. 20 2003 1864 1872 (Pubitemid 37449463)
25. D.E. Owens III, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102 (Pubitemid 41773257)
26. B.A. Pulaski, and S. Ostrand-Rosenberg Mouse 4T1 breast tumor model Curr. Protoc. Immunol. 20 2001 16
27. H. Rouhani, N. Sepehri, H. Montazeri, M.R. Khoshayand, M.H. Ghahremani, and S.N. Ostad et al. Zinc protoporphyrin polymeric nanoparticles: potent heme oxygenase inhibitor for cancer therapy Pharm. Res. 2014 1 16 In Press
28. Y. Saga, H. Mizukami, M. Suzuki, T. Kohno, M. Urabe, and K. Ozawa et al. Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells Clin. Cancer Res. 8 2002 1248 1252 (Pubitemid 34517665)
29. L.B. Saltz, J.V. Cox, C. Blanke, L.S. Rosen, L. Fehrenbacher, and M.J. Moore et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer New Eng. J. Med. 343 2000 905 914
30. P. Sapra, H. Zhao, M. Mehlig, J. Malaby, P. Kraft, and C. Longley et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model Clin. Cancer Res. 14 2008 1888 1896 (Pubitemid 351469476)
31. J.K. Telford A brief introduction to design of experiments Johns Hopkins APL Tech. Dig. 27 2007 224 232 (Pubitemid 351652795)
32. J. Vandervoort, and A. Ludwig Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study Int. J. Pharm. 238 2002 77 92 (Pubitemid 34457877)
33. C. Vauthier, and K. Bouchemal Methods for the preparation and manufacture of polymeric nanoparticles Pharm. Res. 26 2009 1025 1058
34. J. van Ark-Otte, M. Kedde, W. Van Der Vijgh, A. Dingemans, W. Jansen, and H. Pinedo et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells Br. J. Cancer 77 1998 2171
35. A. Wang, and S. Li Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect BMC Biotechnology 8 2008 46
36. L. Wang, Z. Liu, D. Liu, C. Liu, Z. Juan, and N. Zhang Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity Int. J. Pharm. 413 2011 194 201
37. L. Zhang, M. Yang, Q. Wang, Y. Li, R. Guo, and X. Jiang et al. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice J. Control. Release 119 2007 153 162 (Pubitemid 46754506)